CLEAR-AD.ORG
Updated 38 days ago
Existing cerebrospinal fluid (CSF) and neuroimaging measures of amyloid ß, tau and neurodegeneration (A,T,N) serve as useful diagnostic biomarkers for Alzheimer's disease (AD), however there remains an urgent, unmet need for blood based biomarkers in AD. First, multi-omic studies discovered many perturbed biological pathways in AD, however, systematic studies for biomarkers that capture these diverse biological facets of AD are limited. Second, AD is a heterogeneous disorder but biomarkers that can distinguish the biological subtypes of AD are lacking. Third, core AD neuropathology often co-exists with other neuropathologies such as vascular disease (V). These co-morbidities and co-pathologies need to be considered in biomarker discovery. Fourth, existing biomarker studies are heavily focused on non-Hispanic Whites (NHW). Similar studies in underrepresented populations (URP) are needed. This U19, bringing together >40 experts across 13 institutions, aims to bridge these knowledge gaps..